We previously defined two distinct cell-specific DNA elements controlling the transient expression of the transthyretin gene in Hep G2 (human hepatoma) cells: a proximal promoter region (-202 base pairs [bp] to the cap site), and a far-upstream cell-specific enhancer located between 1.6 and 2.15 kilobases (kb) 5' of the cap site (R. H. Costa, E. Lai, and J. E. Darnell, Jr., Mol. Cell. Biol. 6:46974708, 1986). In this report, we located the effective transthyretin enhancer element within a 100-bp region between 1.96 and 1.86 kb 5' to the mRNA cap site. In Hep G2 nuclear extracts, three protein-binding sites within this minimal enhancer element were identified by gel mobility and methylation protection experiments. Each binding site was required for full enhancer activity in Hep G2 transient expression assays. Competition experiments in protein-binding assays suggested that two of the three sites were recognized by a similar factor and that the protein interaction with the third site was different. The nuclear protein(s) which bound to the two homologous sites was found mainly or only in cells of hepatic origin, suggesting an involvement of this region in the cell-specific function of this enhancer. The nuclear protein(s) recognizing the third enhancer region was also found in HeLa and spleen cells.
The control of differentiated gene expression lies mainly at the level of transcriptional initiation (11) . In a number of different tissue-specific genes, multiple cis-acting DNA elements are necessary for full transcriptional activity, and these occur in three general control regions. (i) Within 100 nucleotides 5' to the cap site are DNA sequence motifs which are common to most mammalian RNA polymerase II promoters (e.g., CCAAT, spl, and TATA boxes [6, 14, 24, 41, 49] ). (ii) Sequences between -100 and -300 nucleotides may contain several separate elements that are required for cell-specific transcription (4, 8, 9, 23, 43-45, 56, 58) . (iii) Both cell-specific and nonspecific enhancer elements may be found within a few hundred to 10,000 bases 5' of the RNA start site (9, 10, 15, 22, 27, 29, 46, 52, 57, 59) . The necessary enhancer elements are also known in individual instances to occur within an intron of the gene (5, 21, 47) or downstream to the poly(A) addition site (28) .
Cell-specific DNA elements apparently mediate their effects on transcription through interaction with a trans-acting protein factor(s) (2, 4, 23, 32-35, 37, 42, 50, 51, 53, 55) . Therefore, these sequences can be used for in vitro binding reactions to identify and purify these factors (6, 33) . Recent reports indicate that certain factors necessary for immunoglobulin gene transcription may be restricted in their distribution if not present only in cells of lymphocytic origin (32, 51, 53, 55) . We have been engaged in examining genes whose transcription occurs predominantly in the liver (3, 4, 10, 11, 17, 18) , an advantageous tissue for the study of cell-specific expression because a single cell type, the hepatocyte, makes up 90% of the tissue mass (25, 26) and because many genes are under coordinate control. If this coordinate transcriptional control is brought about by a limited number of hepatocyte-specific factors, each activating groups of liverspecific genes, then a comparison of the DNA regulatory * Corresponding author.
regions of different liver-specific genes and their cognate nuclear-binding proteins should reveal such a mechanism. At issue is whether hepatocyte-specific regulation makes use of various combinations of generally available factors or whether any of the factors are limited in their distribution to hepatocytes.
We earlier described the isolation of the mouse genomic clone for the transthyretin (TTR) gene, which is transcribed in adults mainly in the liver (10, 12, 54) and choroid plexus cells lining the ventricles in the brain (12) . In rodents, the protein is made and secreted to serve various carrier functions (e.g., thyroid hormone transport in the serum and cerebrospinal fluid [12, 54] ). Our previous report described the identification of two distinct DNA elements located 5' to the mRNA cap site which were responsible for cell-specific expression of TTR and for its high rate of transcription (10) . A promoter-proximal region from -108 to -202 base pairs (bp) (with respect to the cap site) was required for transient expression in Hep G2 (human hepatoma) cells, and a distant enhancer element located between -1.6 and -2.15 kilobases (kb) was found that stimulated the expression from promoter-proximal constructs between 5-and 10-fold. The proximal (-200 bp to the cap site) promoter element did not support expression in HeLa cells and could not be stimulated by the simian virus 40 (SV40) enhancer in that cell type. The TTR distant enhancer was also cell specific, since it could simulate transient expression of the ,-globin promoter in Hep G2 cells but not in HeLa cells.
In the present work we precisely locate the DNA sequences responsible for enhancer function. We then establish that proteins recognize three sites in the enhancer by in vitro binding assays with Hep G2 nuclear extracts. All three protein-binding sites are required for full enhancer function, providing evidence of their importance in transcription. Two of the three sites are related; proteins that recognize these sites are limited in their cellular distribution, suggesting that this region is responsible for the cell-specific nature of this enhancer. A more general nuclear factor present in several cell types interacts with a third enhancer site.
MATERIALS AND METHODS
Construction of TTR enhancer deletions. The construction of the TTR enhancer and promoter minigene plasmids has been described previously (10) . TTR enhancer deletions were made from the SstI (-1.6 kb) site within the -2.15-kb TTR minigene construct or from the NcoI (-2.15 kb) site within the -3-Kb TTR minigene plasmid with the enzyme Bal 31 exonuclease (36) . At several time points after digestion, the DNA ends were made flush with the Klenow fragment of DNA polymerase I, and the plasmid was recircularized after the ligation of an XhoI linker at the deletion site (38) . This population of ligated DNA molecules was used to transform Escherichia coli MC1061, and several different enhancer deletions were selected by restriction enzyme analysis of plasmid minipreparations (38) . The endpoints of these enhancer deletion plasmids were determined by DNA sequencing (48) and were named from the number of nucleotides that were removed from either the NcoI or SstI restriction site. These deletions were then placed in the -202 TTR promoter minigene by using convenient sites within the pGem polylinker (Promega Biotech), which is present in both orientations 5' on this TTR enhancerless minigene (10 Transfection and RNase T2 analysis. Human hepatoma (Hep G2) cells (30) were maintained as monolayer cultures and grown in Ham F12 medium supplemented with 5% fetal calf serum, half the concentration of amino acids in minimal essential medium (GIBCO Laboratories), garamycin (25 FLg/ml), and insulin (Eli Lilly & Co.) 0.5 U/ml). Hep G2 cells were transfected at 50% confluency in Dulbecco modified Eagle medium supplemented with 10% fetal calf serum by the calcium phosphate DNA coprecipitation method as described previously (7, 10) . TTR enhancer deletion constructs (40 FLg) were cotransfected with the SV40 enhancer-3-globin promoter construct (5 pug) into Hep G2 cells, and cytoplasmic RNA was isolated by the Nonidet P-40 lysis (38) method 36 h later. Expression levels were determined by RNase T2 digestion of hybrids between transfected RNA and labeled antisense RNA probes specific to the mouse TTR exon 1 and 3-globin exon 1 as described previously (10) . The protected hybrids were subjected to electrophoresis through a denaturing 8% polyacrylamide gel (39), followed by autoradiography. The TTR signals were standardized for transfection efficiency with the P-globin expression level before comparisons were made with the enhancerless construct to determine the fold enhancer stimulation.
Electrophoretic mobility shift analysis. Nuclear extracts were prepared from cultured cells by the protocol of Dignam et al. (13) at a final NaCl concentration of 0.4 M to extract proteins from the nuclei. The nuclear extracts were prepared from fresh tissue by the method of Gorski et al. (23) . Gel shift experiments (16, 20) Methylation protection experiments. High-specific-activity 3'-end-labeled probes were made by filling in a DNA restriction site with 100 ,uCi of all four [32P]deoxynucleotides (New England Nuclear Corp.; 3,000 Ci/mmol) with the Klenow fragment of DNA polymerase I, followed by phenol-chloroform extraction and ethanol precipitation (38) . The DNA was recut with a second restriction enzyme, and the fragment was gel purified on a low-melting-point agarose gel (Bethesda Research Laboratories). The methylation protection or footprint experiment (19) involved incubating 20 (Fig. 1) (36) . These enhancer deletions were made and used in two types of constructions: (i) all upstream sequences except for the deletions from the Sstl site were left in place, leading to the minigene construction [exon 1, intron 1, and exon 2 joined to the SV40 early region containing the 3' exon and poly(A) site (10)] and (ii) a set of the TTR enhancer deletions were fused at -202 of the TTR promoter, followed by the same minigene construction described above (Fig. 1) . The TTR enhancer deletion constructs were cotransfected into Hep G2 cells along with an SV40 enhancer-,B-globin promoter construct (10, 17) that was used to monitor variations in transfection efficiency. Expression from these constructs was determined by hybridizing two different 32P-labeled antisense RNA probes to . The deletions were named by the number of nucleotides removed from either the Sstl or NcoI cleavage site and are designated by a delta. Deletions in the enhancer region were also joined (lines 5 through 13) with a construct beginning at -202 that included the same minigene construction as above. The various constructs were transfected into Hep G2 cells along with a control ,-globin plasmid, and cytoplasmic RNA was extracted and assayed after 36 h with two separate antisense RNA probes specific for the TTR exon 1 (SP6 probe) and mouse ,-globin exon 1 (10) (position not shown). The results of the expression assays represent the extent of stimulation above expression with the enhancerless plasmid (fold induction over -329; R represents reverse enhancer orientation). The box labeled enhancer indicates the position of the minimal FTR enhancer regions based on these results. (Bottom) Migration of the T2 RNAse-protected products for the FTR exon 1 and the P-globin exon 1. Numbered lanes refer to the corresponding enhancer drawings. As described in the text, each sample was normalized to the 0-globin signal before comparison for FTR expression. The extent of stimulation induction for the full-length EcoRI (-3 kb) constructs compared with the enhancerless construct was 6.4-, 11.6-, and 7.0-fold in the three separate experiments indicated by A, B, and C, respectively. cytoplasmic RNA from the transfected cells, followed by RNase T2 digestion and electrophoresis of the T2 RNaseresistant hybrids through a sequencing gel (10, 40) . The RNA probes used were specific to the mouse TTR exon 1 (diagrammed in Fig. 1 ), which detected specific initiation from all the enhancer minigene constructs and to the mouse P-globin exon 1 (10) . The autoradiograms of gels are presented from the RNase T2 analysis of cytoplasmic RNA isolated from Hep G2 cells that had been transfected with the various constructs containing the TTR enhancer deletions ( 
aUagoA n -k * sm t 1 '.. the various experiments were normalized to the ,-globin exon signal for the comparisons.) As described previously (10) , full TTR enhancer function was retained by constructs that contained sequences between the SstI (-1.6 kb) and NcoI (-2.15 kb) restriction sites (Fig. 1A , compare lane SstI-1.6 kb with lane 1). SstI deletions with the enhancer residing at its normal position showed that removal of 253 bp from the SstI site had no effect on enhancer function (Fig. 1A, compare lanes 1 to 3) . Removal of an additional 78 bp completely eliminated enhancer activity (Fig. IA, lane 4) , defining the 3' boundary of the enhancer region at approximately -1.86 kb. These enhancer deletion fragments, when attached in either orientation to the -202 TTR construct, showed a similar loss in enhancer function with successive removal of DNA sequences (Fig. 1A, lanes 5 through 7; Fig. 1B , lanes SR through 7R). The level of enhancer stimulation by the -3 kb construct was higher in experiment B and resulted in higher activation observed for the enhancer deletion placed in the opposite orientation. The 5' boundary of the enhancer was defined first by the observation that no sequences upstream of 1.96 kb (the AccI site) were required (Fig. 1B, lanes 8 through 10). The element was further delimited by two deletions (Fig. 1C, lanes 12 and 13) , in which removal of only 17 or 57 nucleotides from the AccI site produced significant reductions in enhancer activity (Fig. 1C , compare with lane 11). These enhancer deletions, when cloned in front of the -202 construct in the reverse orientation, again demonstrated this loss in enhancer activity (Fig. 1C, lanes 11R  through 14R) . From the data for the deletion mutants, full enhancer activity was located within a 100-bp region located between the Accl site at -1.96 kb and the Sstl deletion ending at -1.86 kb.
Two nuclear protein-binding sites within the TTR enhancer region are recognized by a cell-specific factor(s). To initially determine functional protein-binding sites within the TTR enhancer, two probes ( Fig. 2A) were analyzed for interaction with nuclear proteins from Hep G2 cells by the gel mobility or gel shift assay (16, 20) . In this assay, a labeld DNA fragment is incubated with nuclear extract (13) in the presence of sufficient amounts of poly(dI dC):poly(dI dC) to compete for nonspecific DNA binding. When this mixture is subjected to electrophoresis through a nondenaturing acrylamide gel, a small percentage (1 to 10%) of the DNA bound to protein migrates more slowly than free probe. Three bands were detected by autoradiography after incubating either probe A or B with Hep G2 nuclear extract (Fig.  2B, lanes marked -) . These bands were not apparent in the absence of nuclear extract (Fig. 2BW lanes PA and PB) The gel-shifted bands did not form ("were competed for") when unlabeled homologous competitor (in 50-fold molar excess) was present during the incubation of labeled DNA with Hep G2 nuclear protein, indicating specificity in the formation of the DNA-protein complex (Fig. 2B, lanes marked +) . Extracts from HeLa cells, which do not express the TTR recombinant gene after transfection (10), produced only very weak bands, the most prominent of which was not specifically competed for by the homologous probe (Fig. 2B , compare + and -lanes). This HeLa nuclear extract was demonstrated to be active for the in vitro transcription of the adenovirus major late promoter (data not shown). These data suggest that the TTR enhancer region contains at least two separate binding sites which interact specifically with hepatoma nuclear proteins and that these proteins, if present, are not in an active form in HeLa cell nuclei. Since this enhancer element was not able to activate the 3-globin promoter in HeLa cells, these results suggest that the binding activity of these proteins is required for enhancer function and that they are candidates for liver-specific transcription factors.
Two protein-binding sites within the TTR enhancer region are homologous. By using the gel shift assay, a more refined analysis of the location of the binding sites within the TTR enhancer was carried out. A restriction map of the DNA from the NcoI to SstI sites, showing the position of the minimal enhancer element and deletions within the enhancer that were used as competitors, appears in Fig. 3A . A 32P-labeled DNA fragment that contained the enhancer binding site defined by probe B (Fig. 2) was incubated with Hep G2 nuclear extract either alone or in the presence of a 50-fold molar excess of each gel-purified DNA fragment as competitor. The results of the interactions were then analyzed by the gel shift assay (Fig. 3B) . With no competitor, three protein-DNA bands (Fig. 3B, labeled B1 , B2, and B3) migrated on the nondenaturing acrylamide gel more slowly than the free probe (labeled F). The presence of the three bands was not affected by the 50-fold molar excess of a fragment located either upstream or downstream of the enhancer region (Fig. 3B, lanes 1 and 2) . However, the three shifted bands were specifically competed for with an excess of each and every part of the minimal enhancer region (Fig.  3B, lanes 3 through 8) . Thus, the specific binding site(s) for Fig. 1 Fig. 1). (B) Gel shift experiment (16, 20, 31) carried out by incubating probe A or B in the absence (-) or presence (+) of unlabeled competitor DNA with nuclear extracts (13) protein lay within this -100-nucleotide stretch and not within adjacent regions which lacked the ability to augment transcription. Since each half of the TTR enhancer region produced three bands in the gel-shift assay (Fig. 2) , it seemed likely that at least two binding sites existed. These two sites contained some homologous region because of the competition observed (Fig. 3) with nonoverlapping DNA fragments from the 5' portion of the TTR enhancer (lanes 4 and 5).
Hep G2 nuclear proteins protect sequences within the TTR enhancer region from DMS methylation. To identify more precisely the nucleotides involved in binding within the TTR enhancer region, DMS or methylation protection (footprint) experiments (19) were done. Labeled DNA fragments from within the enhancer element (Fig. 4) were incubated with Hep G2 nuclear extracts under the gel shift conditions and then treated with DMS prior to purification of the bound (B1, B2, and B3) and free (F) DNA bands on a preparative acrylamide gel (Fig. 3B ). The eluted bands were then cleaved with piperidine and compared on a sequencing gel (39) Fig. 3 , and probe B was obtained by using the delta Nco 202 deletion (Fig. 1, line 12 ) digested with restriction endonuclease enzyme Fokl; each was uniquely 3-end labeled (asterisks). The probes were interacted with nuclear extract and then treated with DMS and subjected to electrophoresis in a nondenaturing buffer. After DMS treatment, the protein-bound DNA (Fig. 3, bands B1 . B2, and B3) was isolated, as was free probe (Fig. 3, band F) . The eluted DNA was deproteinized, subjected to piperidine cleavage, and analyzed on a denaturing 12% acrylamide gel (39) . In addition to the analysis of bands Bi, B2, B3. and F, lanes with the DNA probe not reacted with protein and subjected to breakage at G's or G+A's is shown (one set of lanes contained half the amount of labeled DNA). The sequence around the protected region is shown to the right, and the protected region is indicated by the nucleotide numbers, with the AccI (-1.96 kb) restriction site used as the initial base (also see Fig. 5 for sequence). heparin-agarose column, and fractions were eluted with an increasing KCI gradient and assayed for enhancer binding with probe B (data not shown). This provided 10-fold purification, which was sufficient to give success in a DMS protection experiment (Fig. 4, probe B) . Comparison of the free and the bound lanes generated from probe B revealed a partial footprint beginning at nucleotide 32 and extending to nucleotide 44 (Fig. 4, probe B ; compare lane F with lanes Bi, B2, and B3). Again, all three bound species were protected in the same DNA region and indicated a protein complex similar to the one already described for probe A. The sequence of the enhancer region is presented at the top of Fig. 5 . Comparison of the nucleotides involved in the binding between enhancer probes A and B revealed no striking sequence identity, but they did share two sequence motifs. In probe A, between nucleotides 79 and 89, there were the overlapping oligonucleotides TTACTC and CAA-CAT. Similar oligonucleotide stretches, CAAACAT and ATACTC, existed in the Probe B region (Fig. 5 , nucleotides 28 to 45), but the order of the oligonucleotides was changed and the motifs were separated by 6 nucleotides in the probe B region. However, the homology may be significant because these sequence motifs lay in the region of protein-DNA contact detected by the methylation protection footprint.
Each protein-binding region within the TTR enhancer element is required for full enhancer activity. Whether the protein-binding sites were important for the function of the TTR enhancer was tested by analyzing RNA production from plasmids with internal deletions in the enhancer region after transfection into Hep G2 cells. Each deletion of the enhancer region was joined at -202 in the TTR promoter region. A diagram of the DNA remaining in each deletion and the transfection results (along with cotransfectedglobin as a control) are shown in Fig. 5 .
After normalization to the 3-globin signal, the effect of each deletion on enhancer function could be determined (fold induction, Fig. 5 ). Deletion of the two footprint sites (Fig. 5, lanes 3 through 6) each decreased enhancer activity significantly (compare lanes 3 through 6 with lanes 1 and 2 in Fig. 5 ). The reduction of enhancer activity in construct 6 was due to removal of the internal binding site, since a control plasmid (construct 7) which contained an XhoI linker at this same junction did not affect enhancer function (Fig. 5,  compare lanes 7 and 1) . In addition, deletion of 17 nucleotides at the left end of the enhancer region (Fig. 5, lane 9 ) also significantly reduced activity (compare with lane 8). Thus, this analysis confirmed the functional importance of the defined protein(s)-binding site(s) and suggested a third possible binding site.
Oligonucleotides confirm three binding sites. For a more discriminating assay to investigate the proteins that interact with the TTR enhancer, double-stranded oligonucleotides were made to three DNA regions (Fig. 6 , designated oligomers 1, 2, and 3). Oligomer 1 corresponded to the 5' region of the enhancer shown in Fig. 5 to be required for enhancer function. Oligomers 2 and 3 each included one of the-two regions of DNA binding detected by footprint analysis which were also shown to be required for enhancer activity by deletion analysis. Each oligonucleotide was end labeled, and gel shift experiments with Hep G2 nuclear extracts were carried out with each (Fig. 6) . Oligomer 1 formed two slowly migrating bands, one of which could be competed with by unlabeled oligomer 1. Neither band was competed with by a 100-fold excess of either oligomer 2 or 3. Oligomer 2 formed three slowly migrating bands which were reminiscent of the pattern exhibited with enhancer probes presented in Fig. 2  and 3 . The gel shift bands for labeled oligomer 2 were competed for by a 10-to 20-fold molar excess of homologous oligomer as well as by oligomer 3, yet no effect was detected by the inclusion of a 100-fold excess of oligomer 1 in this binding reaction. A similar situation was found with labeled oligomer 3; self-competition and cross-competition with oligomer 2 were observed, and oligomer 1 had no effect. Thus, the earlier suggestion of homology between the enhancer regions that gave the methylation protection footprints was borne out by the cross-competition of oligomers 2 and 3. Obviously, the binding in the region of oligomer 1 was due to a different factor(s). These results demonstrated that at least three different sequences interact with Hep G2 nuclear proteins to elicit the effect of this enhancer and that two of these sites are recognized by a similar protein complex.
Nuclear proteins that recognize TTR enhancer sequences include cell-specific and common factors. Transcriptional analysis with nuclei isolated from cells of different tissues has demonstrated that the TTR gene is transcribed in hepatocytes or hepatoma cells but not, for example, in HeLa, kidney, or spleen cells (10, 11) . Therefore, the presence in different cells of proteins that would interact with the three oligomers was explored. Nuclear proteins that interacted with oligomer 1 were found in approximately equal amounts in Hep G2 and HeLa cell extracts, each extract producing two bands (Fig. 7, lanes 1 and 2) , one of which exhibited partial and one complete self-competition (Fig. 7, lanes 5 and  6) . Liver and spleen extracts also contained factors that reacted with oligomer 1; liver contained three to four times the specific activity (Fig. 7, lanes 3 and 4) . All of the oligomer 1 protein complexes could be specifically competed for by a 50-fold excess of unlabeled oligomer 1 (Fig. 7, lanes  7 and 8) . These results showed that the nuclear protein(s) recognizing oligomer 1 was present in every cell type tested, varying somewhat in concentration.
Protein-binding experiments with labeled oligomer 3 showed strong specific interaction with Hep G2 and liver nuclear extracts (Fig. 7, lanes 1 and 3) , no detectable specific reaction with HeLa nuclear extract (Fig. 7, lane 2) , and a very weak reaction with spleen nuclear extract (Fig. 7, lane  4) . In addition, the liver extract had the ability to form large amounts of slowly migrating (higher-order) complexes, indicating either a higher concentration of some protein or the presence of a factor not present in spleen nuclei. This higher-order complex did form when the concentration of Hep G2 extract was increased in the binding reaction mix-FIG. 5 . Definition of three regions within the minimal TTR enhancer region required for full activity in Hep G2 transient expression assays. Shown is the DNA sequence of the minimal enhancer region with the location of restriction sites and enhancer deletion points (indicated by del) that were used in the construction of these various plasmids. Also indicated on the sequence are the nucleotides protected from methylation by DMS (* signifies strong protection and + signifies either weak protection of G residues or discernible protection of A residues). Drawn colinear with the sequence is the DNA contained within each enhancer deletion and analyzed after joining to the -202 TTR construct by transfection into Hep G2 cells. Assay for expression was protection against nuclease digestion of labeled antisense RNA as in Fig. 1 .
Numbered lanes refer to the corresponding enhancer drawings. The results of these assays represent the extent of induction over that with the enhancerless minigene (-329). ture (data not shown). Densitometric tracings of the autoradiograms suggested that the amount of oligomer shifted by equal amounts of spleen and liver nuclear extract differed by about 20-fold, and higher-order complex did not appear at all with any spleen extract concentration (Fig. 7, compare lanes  3 and 4) . A nonspecific (noncompetable) band was observed with both HeLa and HepG2 extracts (Fig. 7, lanes 5 and 6) which was not present when nuclear extracts prepared from tissues were used in gel shift experiments with oligomer 3 (Fig. 7, lanes 7 and 8) .
These results suggested that the nuclear factors that recognized the homologous binding sites (oligomers 2 and 3) were responsible for the differential utilization of this enhancer region among the different cell types. Furthermore, the activity of the enhancer element was modulated by the interaction of both cell-specific and common regulatory protein(s). were used in gel shift experiments (see Fig. 6 ) with various extracts (13, 23) to determine the cell distribution of these nuclear-binding proteins. Equivalent amounts (in total protein) of the indicated nuclear extract were used; lanes 1 to 4 contained no competitor oligomer, and lanes 5 to 8 had a 50-fold molar excess of the indicated competitor during the binding reaction. The gel shift analysis was performed on a low-ionic strength 9o acrylamide gel, and shown is the top portion of the gel revealing the protein-bound bands.
DISCUSSION
We have localized the cell-specific enhancer of the TTR ,.~g ene to a 100-bp region located far upstream (between 1.96 and 1.86 kb) from the mRNA cap site. Within the enhancer region, three distinct binding sites for hepatoma nuclear _ -** proteins were detected by gel shift and footprint assays. Each of these sequences was required for full enhancer activity in plasmids transfected into Hep G2 cells. Two of these binding sites were within the regions protected by protein from DMS methylation and exhibited cross-competition in gel shift assays even though they did not possess complete sequence identity. Nuclear extracts prepared from HeLa cells, a cell line in which the TTR enhancer does not function (10) , clearly lacked the ability to efficiently bind the two related enhancer regions; however, HeLa cell extracts did possess binding activity for the third enhancer site. This third site (oligomer 1) could be recognized by an enhancer recognition protein such as Apl, which is found in many different cell types (1, 33, 34 (10) . In fact, the cell-specific TTR enhancer oligomers 2 and 3 will compete efficiently with this promoter region in gel shift experiments with Hep G2 extracts, while the unrelated oligomer 1 has no effect in disrupting protein binding (Costa and Darnell, unpublished observations). This situation is similar to that observed with the promoter and enhancer of the heavy-chain immunoglobulin gene (53, 55) , in which an octamer sequence is present in both regions and is required for transcriptional activity. Furthermore, the octamer sequence will compete for the binding of nuclear proteins in these DNA regions. The 
